Poseida Therapeutics PSTX

$ 2.73 0.18%

Quarterly report 2024-Q3
added 11-07-2024

Poseida Therapeutics Income Statement 2011-2024 | PSTX

Annual Income Statement Poseida Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	306 M	363 M	424 M	478 M	-	-	-	-	-	-	-	-	-
Shares	90.2 M	72 M	62.2 M	55 M	-	-	-	-	-	-	-	-	-
Historical Prices	3.39	5.04	6.81	11	-	-	-	-	-	-	-	-	-
Net Income	-123 M	-64 M	-125 M	-130 M	-86.5 M	-44.4 M	-19.7 M	-	-	-	-	-	-
Revenue	64.7 M	130 M	31.2 M	-	-	-	2.98 M	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-130 M	-59.9 M	-141 M	-127 M	-85.5 M	-	-	-	-	-	-	-	-
Interest Expense	8.67 M	6.37 M	3.36 M	3.51 M	3.55 M	-	-	-	-	-	-	-	-
EBITDA	-124 M	-54.8 M	-137 M	-124 M	-77.7 M	-38.8 M	-20.9 M	-	-	-	-	-	-
Operating Expenses	194 M	190 M	173 M	127 M	78.8 M	40.6 M	24.6 M	-	-	-	-	-	-
General and Administrative Expenses	37.4 M	37.5 M	35.9 M	23 M	18.5 M	9.67 M	5.48 M	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Poseida Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	97.2 M	97 M	96 M	95.6 M	91.9 M	86.8 M	86.3 M	86 M	76.3 M	62.7 M	62.6 M	62.5 M	62.3 M	62.2 M	62 M	61.9 M	55 M	13.4 M	13.3 M	13.2 M	12.7 M	12.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	20.2 M	-31.4 M	-24.3 M	-	-31.8 M	-27.5 M	-38.8 M	-	70.4 M	-43 M	-58.1 M	-	-42.4 M	-45.7 M	-38.3 M	-	-34.4 M	-30.4 M	-28.8 M	-	-86.5 M	-86.5 M	-13.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	71.7 M	26 M	28.1 M	-	9.35 M	20 M	10.3 M	-	116 M	2.7 M	1.44 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	19.7 M	-31.8 M	-24.6 M	-	-36.2 M	-27.9 M	-39.5 M	-	71.8 M	-41.5 M	-57 M	-	-41.6 M	-44.9 M	-37.5 M	-	-33.5 M	-29.4 M	-28.3 M	-	-20.8 M	-28.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	2.3 M	2.26 M	2.25 M	-	2.24 M	2.14 M	2.03 M	-	1.78 M	-1.54 M	1.08 M	-	837 K	843 K	838 K	-	848 K	892 K	914 K	-	935 K	903 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	21 M	-30.5 M	-23.2 M	-	-34.8 M	-26.5 M	-38.2 M	-	73.2 M	-40.2 M	-55.8 M	-	-40.4 M	-43.8 M	-36.4 M	-	-32.8 M	-28.9 M	-27.9 M	-	-20 M	-27.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	52 M	57.7 M	52.7 M	-	45.6 M	47.9 M	49.9 M	-	44.5 M	44.2 M	58.4 M	-	41.6 M	44.9 M	37.5 M	-	33.5 M	29.4 M	28.3 M	-	20.8 M	28.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	10.1 M	12.2 M	9.8 M	-	8.09 M	8.68 M	11.8 M	-	9.39 M	9.24 M	9.55 M	-	9.07 M	8.87 M	8.37 M	-	6.46 M	4.24 M	4.85 M	-	4.01 M	4.04 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency